Barinthus Bio VTP-300 data: 76% eligible to stop NUC therapy; significant HBsAg reduction vs placebo

Barinthus Biotherapeutics plc.

HBV003 (Phase 2b): 76% (16/21) eligible for NUC discontinuation; 19% achieved undetectable HBsAg.
IM-PROVE II (Phase 2a): statistically significant HBsAg reduction at 24 weeks post-EOT (p<0.05) vs placebo.
84% of VTP-300 group (16/19) met criteria to discontinue NUC therapy at EOT vs 52% placebo.
All treatment groups well-tolerated; no SAEs or Grade 3/4 treatment-related AEs in either trial.
Data cutoffs: April 15, 2024 (HBV003) and April 12, 2024 (IM-PROVE II); presented at EASL Congress 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.